The saliva-based EFIRM platform shows good concordance to plasma-based platforms (ddPCR and NGS) for longitudinally monitoring the combination of EGFR and PIK3CA ctDNA and may be a valuable platform for liquid biopsy MRD in NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.